282 related articles for article (PubMed ID: 14699013)
1. Alpha4beta1 integrin mediates selective endothelial cell responses to thrombospondins 1 and 2 in vitro and modulates angiogenesis in vivo.
Calzada MJ; Zhou L; Sipes JM; Zhang J; Krutzsch HC; Iruela-Arispe ML; Annis DS; Mosher DF; Roberts DD
Circ Res; 2004 Mar; 94(4):462-70. PubMed ID: 14699013
[TBL] [Abstract][Full Text] [Related]
2. Modulation of endothelial cell proliferation, adhesion, and motility by recombinant heparin-binding domain and synthetic peptides from the type I repeats of thrombospondin.
Vogel T; Guo NH; Krutzsch HC; Blake DA; Hartman J; Mendelovitz S; Panet A; Roberts DD
J Cell Biochem; 1993 Sep; 53(1):74-84. PubMed ID: 8227183
[TBL] [Abstract][Full Text] [Related]
3. Thrombospondin-1 inhibits endothelial cell responses to nitric oxide in a cGMP-dependent manner.
Isenberg JS; Ridnour LA; Perruccio EM; Espey MG; Wink DA; Roberts DD
Proc Natl Acad Sci U S A; 2005 Sep; 102(37):13141-6. PubMed ID: 16150726
[TBL] [Abstract][Full Text] [Related]
4. Interaction of alpha9beta1 integrin with thrombospondin-1 promotes angiogenesis.
Staniszewska I; Zaveri S; Del Valle L; Oliva I; Rothman VL; Croul SE; Roberts DD; Mosher DF; Tuszynski GP; Marcinkiewicz C
Circ Res; 2007 May; 100(9):1308-16. PubMed ID: 17413041
[TBL] [Abstract][Full Text] [Related]
5. Domain swapping in a COOH-terminal fragment of platelet factor 4 generates potent angiogenesis inhibitors.
Hagedorn M; Zilberberg L; Wilting J; Canron X; Carrabba G; Giussani C; Pluderi M; Bello L; Bikfalvi A
Cancer Res; 2002 Dec; 62(23):6884-90. PubMed ID: 12460903
[TBL] [Abstract][Full Text] [Related]
6. Recognition of the N-terminal modules of thrombospondin-1 and thrombospondin-2 by alpha6beta1 integrin.
Calzada MJ; Sipes JM; Krutzsch HC; Yurchenco PD; Annis DS; Mosher DF; Roberts DD
J Biol Chem; 2003 Oct; 278(42):40679-87. PubMed ID: 12909644
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of angiogenesis by thrombospondin-2.
Volpert OV; Tolsma SS; Pellerin S; Feige JJ; Chen H; Mosher DF; Bouck N
Biochem Biophys Res Commun; 1995 Dec; 217(1):326-32. PubMed ID: 8526929
[TBL] [Abstract][Full Text] [Related]
8. Lumen formation and other angiogenic activities of cultured capillary endothelial cells are inhibited by thrombospondin-1.
Tolsma SS; Stack MS; Bouck N
Microvasc Res; 1997 Jul; 54(1):13-26. PubMed ID: 9245640
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the mitogenic, angiogenic and tumorigenic activities of pleiotrophin by a synthetic peptide corresponding to its C-thrombospondin repeat-I domain.
Hamma-Kourbali Y; Bernard-Pierrot I; Heroult M; Dalle S; Caruelle D; Milhiet PE; Fernig DG; Delbé J; Courty J
J Cell Physiol; 2008 Jan; 214(1):250-9. PubMed ID: 17607711
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of FGF-2-mediated chemotaxis of murine brain capillary endothelial cells by cyclic RGDfV peptide through blocking the redistribution of c-Src into focal adhesions.
Shono T; Mochizuki Y; Kanetake H; Kanda S
Exp Cell Res; 2001 Aug; 268(2):169-78. PubMed ID: 11478843
[TBL] [Abstract][Full Text] [Related]
11. Thrombospondin-1 type 1 repeat recombinant proteins inhibit tumor growth through transforming growth factor-beta-dependent and -independent mechanisms.
Miao WM; Seng WL; Duquette M; Lawler P; Laus C; Lawler J
Cancer Res; 2001 Nov; 61(21):7830-9. PubMed ID: 11691800
[TBL] [Abstract][Full Text] [Related]
12. Syndecan-4 contributes to endothelial tubulogenesis through interactions with two motifs inside the pro-angiogenic N-terminal domain of thrombospondin-1.
Nunes SS; Outeiro-Bernstein MA; Juliano L; Vardiero F; Nader HB; Woods A; Legrand C; Morandi V
J Cell Physiol; 2008 Mar; 214(3):828-37. PubMed ID: 17879962
[TBL] [Abstract][Full Text] [Related]
13. Thrombospondin-1 suppresses tumorigenesis and angiogenesis in serum- and anchorage-independent NIH 3T3 cells.
Castle VP; Dixit VM; Polverini PJ
Lab Invest; 1997 Jul; 77(1):51-61. PubMed ID: 9251678
[TBL] [Abstract][Full Text] [Related]
14. The minimal active domain of endostatin is a heparin-binding motif that mediates inhibition of tumor vascularization.
Olsson AK; Johansson I; Akerud H; Einarsson B; Christofferson R; Sasaki T; Timpl R; Claesson-Welsh L
Cancer Res; 2004 Dec; 64(24):9012-7. PubMed ID: 15604266
[TBL] [Abstract][Full Text] [Related]
15. Expression and characterization of novel thrombospondin 1 type I repeat fusion proteins.
Qabar AN; Bullock J; Matej L; Polverini P
Biochem J; 2000 Feb; 346 Pt 1(Pt 1):147-53. PubMed ID: 10657251
[TBL] [Abstract][Full Text] [Related]
16. Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factor.
Mousa SA; Bergh JJ; Dier E; Rebbaa A; O'Connor LJ; Yalcin M; Aljada A; Dyskin E; Davis FB; Lin HY; Davis PJ
Angiogenesis; 2008; 11(2):183-90. PubMed ID: 18080776
[TBL] [Abstract][Full Text] [Related]
17. Canstatin-N fragment inhibits in vitro endothelial cell proliferation and suppresses in vivo tumor growth.
He GA; Luo JX; Zhang TY; Wang FY; Li RF
Biochem Biophys Res Commun; 2003 Dec; 312(3):801-5. PubMed ID: 14680836
[TBL] [Abstract][Full Text] [Related]
18. Endogenous thrombospondin-1 is not necessary for proliferation but is permissive for vascular smooth muscle cell responses to platelet-derived growth factor.
Isenberg JS; Calzada MJ; Zhou L; Guo N; Lawler J; Wang XQ; Frazier WA; Roberts DD
Matrix Biol; 2005 Apr; 24(2):110-23. PubMed ID: 15890262
[TBL] [Abstract][Full Text] [Related]
19. Integrin alpha4beta1 promotes monocyte trafficking and angiogenesis in tumors.
Jin H; Su J; Garmy-Susini B; Kleeman J; Varner J
Cancer Res; 2006 Feb; 66(4):2146-52. PubMed ID: 16489015
[TBL] [Abstract][Full Text] [Related]
20. Role of thrombospondin-1-derived peptide, 4N1K, in FGF-2-induced angiogenesis.
Kanda S; Shono T; Tomasini-Johansson B; Klint P; Saito Y
Exp Cell Res; 1999 Nov; 252(2):262-72. PubMed ID: 10527617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
